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Th17 cells have been implicated in a number of inﬂammatory and autoimmune diseases. The phospholipid mediator platelet-
activating factor (PAF) is found in increased concentrations in inﬂammatory lesions and has been shown to induce IL-6
production. We investigated whether PAF could aﬀect the development of Th17 cells. Picomolar concentrations of PAF induced
IL-23, IL-6, and IL-1β expression in monocyte-derived Langerhans cells (LCs) and in keratinocytes. Moreover, when LC were
pretreated with PAF and then cocultured with anti-CD3- and anti-CD28-activated T cells, the latter developed a Th17 phenotype,
with a signiﬁcant increase in the expression of the transcriptional regulator RORγt and enhanced expression of IL-17, IL-21, and
IL-22. PAF-induced Th17 development was prevented by the PAF receptor antagonist WEB2086 and by neutralizing antibodies
to IL-23 and IL-6R. This may constitute a previously unknown stimulus for the development and persistence of inﬂammatory
processes that could be amenable to pharmacologic intervention.
1.Introduction
A unique subset of interleukin (IL)-17-producing CD4+ T
helper (Th17) cells, distinct from the well-known Th1 and
Th2 cells, was recently identiﬁed. The diﬀerentiation and
persistence of Th17 cells was shown to be dependent on the
presence of selected cytokines that include, in humans, IL-
1β,I L - 6[ 1], and IL-23 [2–4], as well as TGFβ [5]. Th17
cells secrete a range of cytokines, including IL-17A, IL-17F,
IL-21, IL-22, TNFα, and IL-6, which have both overlapping
and distinct roles in host defense and inﬂammation [4,
6]. Retinoic orphan receptor-gamma T (RORγt)3 and, in
humans, its orthologue RORC2 were identiﬁed as markers of
Th17 cells and shown to be master regulatory transcription
factors required for Th17 development [7, 8]. IL-17 appears
to play essential roles not only in host defenses against
various pathogens, but also in the pathogenesis of chronic
inﬂammatory disorders and in many autoimmune diseases,
including multiple sclerosis, inﬂammatory bowel disease,
asthma, and psoriasis [9–15].
Psoriasis is a chronic inﬂammatory skin disorder char-
acterized by hyperplasia of the epidermis, inﬁltration of
leukocytes into both the dermis and the epidermis, as well
as dilatation and growth of blood vessels. Until recently,
psoriasis has been considered mainly to be a Th1-driven
autoimmune inﬂammatory disease, but recent ﬁndings have
clearly revealed a role for IL-23 and Th17 cells. In support of
this, an increased number of Th17 cells has been identiﬁed
in the dermis and epidermis of psoriatic skin compared
with normal skin [16], and these cells are activated based
on increased IL-17A, IL-17C, IL-17F, and IL-22 expression.
Moreover, expression of IL-17A, IL-17F, IL-26, CCL20, and
RORγt, all Th17 markers, were shown to be enhanced in
psoriatic skin [2, 17]. IL-23 was also reported to be highly
expressed in lesional psoriatic skin and to be produced by
keratinocytes, Langerhans cells (LC), dermal dendritic cells
and macrophages [18, 19]. Finally, resolution of psoriatic
lesions has been achieved with the use of several kinds of
immune modulators that block the IL-23/Th17 [20].2 Mediators of Inﬂammation
Platelet-activating factor (PAF) is a potent phospholipid
inﬂammatorymediatorthatisreleasedearlyininﬂammation
by a variety of cell types. PAF acts largely by binding to
its receptor (PAFR), a G-protein-coupled receptor found on
most cells, including platelets, monocytes, mast cells, gran-
ulocytes, B lymphocytes, dendritic cells, and keratinocytes
[21–24]. PAF is a known regulator of transcription and
has been shown to upregulate the secretion of a variety of
cytokines, including IL-1, IL-6, and TNF-α [25, 26]. PAF
has been implicated in the pathogenesis of asthma and
other allergic conditions, in inﬂammatory bowel disease,
rheumatoid arthritis, multiple sclerosis, endotoxic shock,
and dermal inﬂammation [23, 27, 28]. Several observations
suggested a role for PAF in psoriasis. Hence, it was reported
that PAF plasma levels were elevated in patients with
psoriasis and that lesional psoriatic skin contains substantial
amounts of this mediator [29, 30]. Histological analysis has
shown greater PAFR staining in the epidermis of psoriasis
patients compared to controls [31]. A thickened skin with
increased proliferation of epidermal keratinocytes, as is
seen in psoriasis, was observed in transgenic mice which
overexpress PAFR [32].
In the current study, we examined the potential for PAF
to induce Th17 development through activation of LC and
production of IL-6 and IL-23, in a model of LC-T cell
coculture.
2.MaterialsandMethods
2.1.GenerationandIsolationofMonocyte-DerivedLangerhans
Cells. Monocyte-derived LC were generated from human
peripheral blood mononuclear leukocytes (PBML) obtained
from normal donors following informed consent in accor-
dance with an Internal Review Board-approved protocol,
in conformity with the Declaration of Helsinki. Blood
monocytes were puriﬁed by density gradient centrifugation
on Ficoll-Paque (GE healthcare, Piscataway, NJ, USA),
followed by plastic adherence, and were cultured for 5-
6 days in 6-well tissue culture plates (Becton Dickinson
Labware, Franklin Lakes, NJ, USA) at 2 × 106/mL in RPMI
1640 medium supplemented with 10% (v/v) FBS (PAA
Laboratories), rhGM-CSF (20ng/mL), rhIL-4 (20ng/mL)
and rh-TGF-β (10ng/mL) (Peprotech, Rocky Hill, NJ, USA)
at 37◦C in a humidiﬁed 5% CO2 incubator. On day 3,
fresh medium supplemented with the above mentioned
cytokines was added. After 5 days of culture, the outcoming
population consisted of typical immature LC to which
half-strength concentrations of above mentioned cytokines
were added. These LC expressed low levels of CD86, and
were negative for CD83 (BD Pharmingen, Mississauga, ON,
Canada). They were routinely tested for langerin (Beckman
Coulter, Marseille, France) and E-cadherin (R&D Systems,
Minneapolis, Minn, USA) expression, which exceeded 80%
and 75%, respectively.
2.2. Isolation of CD4+ TC e l l s .CD4+ T cells were puriﬁed
from whole blood lymphocytes by depletion of contaminat-
ing cells using a “Human CD4+ T cell enrichment kit” (Stem
Cell technologies, Vancouver, BC, Canada) following the
manufacturer’s instructions. Purity was greater than 98%.
CD4+ T cells at 0.5 × 106 cells/mL in RPMI 1640 10% FBS
were then incubated for 5 days with a combination of anti-
CD3 (2μg/mL), immobilized on microplates, and soluble
anti-CD28(1μg/mL)antibodies.Thetreatmentwaseﬀective
in inducing T cell blastogenesis.
2.3. Coculture of PAF-Stimulated MoLC with T Cells. Tc e l l s
were plated at 1 × 105 cells/well and either stimulated alone
with a combination of IL-1β + IL-6 + IL-23 (Peprotech,
Rocky Hill, NJ and Alexis Biochemicals, San Diego, Calif,
USA) for 5 days or cocultured with 2.5 × 104 autologous
LC in the absence or presence of graded concentrations of
PAF (10−12 to 10−7 M) (octadecyl-PAF, Cayman, Ann Arbor,
Mich, USA). When indicated, neutralizing Ab for IL-6R,
IL-15 or IL-23p19 (R&D Systems) were used at 0.4μg/mL,
0.5μg/mL and 0.8μg/mL, respectively. Cultures were used
after5daysforcytometryandPCRanalysis.Whenindicated,
inhibitors of Jak2 (AG490), EGFR (EGFR Inhibitor), NF-
κB( N F - κB Activation Inhibitor) or STAT3 (STAT3 Inhibitor
Peptide), all from EMD Biosciences, San Diego, Calif, USA,
were at 10μM, 20μM, 20μM and 400μM, respectively.
2.4. Keratinocyte Cultures. The A431 human keratinocytic
squamous cell carcinoma cell line, was obtained from the
American Type Culture Collection and cultured at 37◦Ci n
high-glucose DMEM (Gibco BRL, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (FBS) (PAA
Laboratories, Etobicoke, ON, Canada).
Normal human neonatal foreskin epidermal kerat-
inocytes (NHEK cells) were obtained from Lonza (Walk-
ersville, Md, USA). NHEK cells were grown in serum-
free medium, KGM-2 (Lonza), containing 0.09mmol/L
CaCl2, 0.5mg/mL hydrocortisone, 0.1ng/mL recombinant
human epidermal growth factor (EGF), 5ng/mL insulin,
0.4% v/v bovine pituitary extract, 50mg/mL gentamycin
and 0.05mg/mL amphotericin B, in an atmosphere of 95%
air and 5% CO2 at 37◦C. NHEK cells were used in the
proliferative phase at 70%–80% conﬂuency.
2.5. Flow Cytometry Analysis. For the last 3h of coculture,
c e l l sw e r es t i m u l a t e dw i t h2 5n g / m LP M A( S i g m a - A l d r i c h ,
Oakville, ON, Canada) and 1μg/mL ionomycin (EMD
chemicals, La Jolla, Calif, USA) in the presence of 2mM
monensin (BD Biosciences, Mississauga, ON, Canada) for
assessment of intracellular IL-17A. Cells were then washed
in Fix/Perm solution (eBioscience, San Diego, Calif, USA)
according to the manufacturer’s instructions and stained
for CD4 (BD biosciences) and intracellular IL-17A or
RORγt (eBioscience) for 30 minutes. After washing, cells
were analyzed on a FACSCalibur ﬂow cytometer using the
CellQuestPro software.
2.6. RNA Isolation and Real-Time Quantitative PCR. RNA
was obtained using Trizol reagent (Invitrogen, Burlington,
ON, Canada) according to the manufacturer’s instructions.
After total RNA puriﬁcation with Rneasy kit (Qiagen,Mediators of Inﬂammation 3
Mississauga, ON, Canada), 1.0μgo fR N Aw a sc o n v e r t e dt o
cDNA with oligo dT (Fermentas, Burlington, ON, Canada)
and reverse transcriptase (M-MLV; Promega, Madison, WI,
USA) in a volume of 20μL. GAPDH, IL-6, IL-17A, IL-21, IL-
22, IL-23p19, PAF receptor (PAFR) and RORC2 expression
were measured using real-time PCR performed on a Rotor-
Gene 3000 (Corbett Research, Kirkland, QC, Canada). The
following oligonucleotide primer sets were obtained from
IDT (Coralville, Ind, USA): human GAPDH: forward, 5-
GAT GAC ATC AAG AAG GTG GTG AA-3 and reverse,
5-GTC TTA CTC CTT GGA GGC CAT GT-3; human IL-
6: forward, 5-GTG TGA AAG CAG CAA AGA GGC-3 and
r e v e r s e ,5 - C T GG A GG T AC T CT A GG T AT A C - 3 ;h u m a n
IL-17A: forward, 5-CTA CAA CCG ATC CAC CTC AC-
3 and reverse, 5-CCA CGG ACA CCA GTA TCT TC-3;
human IL-21: forward, 5-GCA ACA TGG AGA GGA TTG
TC-3 and reverse, 5-CTG AAA GCA GGA AAA AGC TG-
3; human IL-22: forward, 5-CAC AGA CGT TCG TCT CAT
TG-3 and reverse, 5-AGC TTT TGC ACA TTC CTC TG-
3; human IL-23p19: forward, 5-GAT GTT CCC CAT ATC
CAG TG-3 and reverse, 5-ATC TGC TGA GTC TCC CAG
TG-3; human PAFR: forward, 5-CCT CCT TAG CAC CAA
CTG TGT C-3 and reverse, 5-CAA CCA CTT CAG TGA
CCG TAT CC-3; human RORC2: forward, 5-CAG TCA
TGA GAA CAC AAA TTG AAG TG-3 and reverse, 5-CAG
GTG ATA ACC CCG TAG TGG AT-3. Each sample for the
real-time PCR consisted of: 1μL cDNA, 2.5mM MgCl2,
100μMd N T P ,1μMo fp r i m e r s ,2 . 5μL of 10X PCR buﬀer,
0.5 unit of Taq polymerase (Feldan Bio Laboratories Inc,
Qu´ ebec, QC, Canada) and 0.8μL of SYBR Green (Molecular
Probe, Eugene, OR; 1/1000 stock dilution) in a reaction
volume of 25μL. The cycling program consisted of an initial
denaturation at 95◦C for 5min, 45 cycles of ampliﬁcation
conditions as follows: 95◦C (30sec), 58◦C (30sec), 72◦C
(30sec), and a ﬁnal extension at 72◦C for 6min. Each gene
expression was normalized with GAPDH mRNA content
and fold diﬀerences were calculated with the delta-delta
(ΔΔ)Ct method according to the following formula: (ΔΔCt
= [(Ct G.O.I.Ctl − Ct HK.G.Ctl) − (Ct G.O.I.STIM. − Ct
HK.G.STIM.)]. Comparison of the expression of each gene
between its control and stimulated states was determined by
its ΔΔCt. Results were then transformed into fold variation
measurements: fold increase = 2ΔΔCt
2.7.StatisticalAnalysis. Statisticalsigniﬁcancewascalculated
using Prism 5 software (GraphPad Software, San Diego
Calif,USA).Foranalysisofdiﬀerencesbetween experimental
groups, Student’s t-test and one-way and two-way ANOVA
with Bonferroni posttest were used, as appropriate. Values of
P ≤ 0.05 were considered statistically signiﬁcant.
3. Results
3.1. PAF Induces IL-23, IL-6, and IL-1β Production. In order
to assess the potential for PAF to modulate Th17 cell
development, we initially exposed monocyte-derived LC to
graded concentrations of PAF and measured their capacity
to express IL-23p19, IL-6, and IL-1β mRNA. As shown in
Figure 1,picomolarconcentrationsofPAFincreasedbothIL-
23, IL-6 and IL-1β gene expression in a 4-hr culture, with
signiﬁcant eﬀects at PAF concentrations of 10−11 to 10−9 M.
SincekeratinocytesalsoexpressreceptorsforPAF(PAFR)
[22], we tested whether PAF could also induce cytokine
expression in these cells. As shown in Figure 2, PAF induced
the expression of IL-23p19, IL-6 and IL-1β mRNA in both
A431 keratinocytic cells (Figures 2(a), 2(b), and 2(c)) and
normal human epidermal keratinocytes (NHEK) (Figures
2(d), 2(e), and 2(f)) with signiﬁcant increases at PAF 10−10
to 10−8 M.
3.2. PAF-Activated LC Induce Th17 Cell Development. Since
antigen-presenting cells, such as LC can modulate T helper
cell polarization, we investigated whether PAF activation of
LC could induce the development of a Th17 phenotype
in cocultured autologous CD4+ T cells. During the 5-day
diﬀerentiation of monocytes into LC, we activated autolo-
gous T cells with anti-CD3 and anti-CD28 Ab. Monocyte-
derived LC expressed both PAFR mRNA and protein, and
were capable of responding to PAF with calcium ﬂux and
chemotaxis. In contrast, activated CD4+ T cells expressed no
PAFR mRNA and failed to respond to PAF in either calcium
ﬂux or chemotaxis.
Following their 5-day diﬀerentiation, LC were treated
with graded concentrations of PAF and put in a coculture
with activated autologous T cells for an additional 5-day
period at a ratio of 1:5. T cells were then analyzed by ﬂow
cytometry for expression of the transcriptional regulator
RORγt and for IL-17. As shown in Figures 3(a) and 3(b),
PAF-activated LC signiﬁcantly enhanced both RORγta n d
IL-17 expression in preactivated and cocultured CD4+ T
cells. Induction of RORγt expression in T cells by PAF-
pretreated LC was of a similar magnitude as that induced
in activated T cells cultured in the presence of IL-1β,I L -
6, and IL-23 without LC. As expected, PAF-induced RORγt
expression in T cells was prevented by pretreatment of LC
with the PAFR antagonist WEB2086 before exposure to PAF,
whereas cytokine-induced RORγt expression was unaﬀected
(Figure 2(c)). Interestingly, exposure of LC to WEB2086
lowered their basal level of RORγt induction, suggesting that
basal RORγt expression was dependent on PAFR activation,
potentially by endogenous production of PAF or PAF-like
compounds by LC.
3.3. PAF-Induced Th17 Development Is Associated with
Enhanced Production of IL-17A, IL-21, IL-22, and RORC2.
Th17 development following coculture with PAF-treated LC
wasaccompaniedbyexpressionofTh17-associatedcytokines
by the CD4+ T cell population, namely IL-17A, IL-21, and
IL-22, as well as RORC2, the closest human homologue of
mouse RORγt. As shown in Figure 4, subnanomolar con-
centrations of PAF were able to induce a signiﬁcant increase
in IL-17A, IL-21, IL-22, and RORC2 mRNA expression.
Interestingly, the PAF-induced LC-dependent levels were
similar to those induced by direct T cell activation with
the combination of IL-1β, IL-6, and IL-23, except for IL-
22, which was expressed more strongly in directly activated4 Mediators of Inﬂammation
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Figure 1: PAF-induced IL-6 and IL-23p19 mRNA expression in LC. Monocyte-derived LC were stimulated with graded concentrations of
PAF or its vehicle (ethanol; V) for 4h. IL-23 p19 (a), IL-6 (b), and IL-1β (c) mRNA was then measured by real-time quantitative PCR. Data
(means ± SEM) are expressed as fold induction relative to vehicle control. n = 9; ∗P<0.05; ∗∗P<0.01.
T cells. In contrast, puriﬁed CD4+ T cells, either freshly
isolated or activated for 5 days with anti-CD3/anti-CD28 Ab,
failed to upregulate their expression of IL-17A or RORC2 in
response to PAF (data not shown).
3.4. PAF-Induced Th17 Development Is Dependent on IL-23
and IL-6. We next investigated whether PAF-induced devel-
opment of Th17 diﬀerentiation was dependent on cytokines
produced by LC. Since IL-15, a proinﬂammatory cytokine,
synthesized mainly by LC and DC, has also been suggested
as an inducer of Th17 cell development [33, 34], we also
used neutralizing anti-IL-15 Ab in our assays. We thus added
neutralizing anti-IL-6R, anti-IL-23 and/or anti-IL-15 Ab to
the LC-T cell cocultures and measured RORγt expressionMediators of Inﬂammation 5
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Figure 2: PAF-induced IL-23p19, IL-6, and IL-1β mRNA expression in A431 keratinocytic cells (a, b, c) and normal human epidermal
keratinocytes (NHEK; d, e, f). Cells were stimulated with graded concentrations of PAF or its vehicle (ethanol; V) for 4h. IL-23 p19 (a, d),
IL-6 (b, e), and IL-1β (c, f) mRNA was then measured by real-time quantitative PCR. Data (means ± SEM) are expressed as fold induction
relative to vehicle control. n = 8; ∗P<0.05; ∗∗P<0.01.6 Mediators of Inﬂammation
0
1
2
3
∗
∗
∗∗
∗∗
∗
∗∗
∗∗
R
O
R
γ
t
e
x
p
r
e
s
s
i
o
n
i
n
C
D
4
+
T
c
e
l
l
s
V
−
1
2
−
1
1
−
1
0
−
9
−
8
−
7
[PAF] log10 (M)
I
L
-
1
β
+
I
L
-
6
+
I
L
-
2
3
(a)
V
−
1
2
−
1
1
−
1
0
−
9
−
8
−
7
0
∗
∗
∗∗
∗
∗
∗∗
∗ ∗∗
[PAF] log10 (M)
2
1.5
1
0.5
I
L
-
1
7
e
x
p
r
e
s
s
i
o
n
i
n
C
D
4
+
T
c
e
l
l
s
I
L
-
1
β
+
I
L
-
6
+
I
L
-
2
3
(b)
V
−
1
0
−
9
[PAF] log10 (M)
0
5
10
15
20
25
30
35
Vehicle
WEB 2086
∗∗
∗∗∗
R
O
R
γ
t
e
x
p
r
e
s
s
i
o
n
(
M
F
I
)
I
L
-
1
β
+
I
L
-
6
+
I
L
-
2
3
(c)
Figure 3: PAF-stimulated LC induce a Th17 phenotype in cocultured T cells. Monocyte-derived LC were stimulated with graded
concentrations of PAF or its vehicle (ethanol; V) and cocultured with antiCD3/CD28-activated CD4+ Tc e l l sf o r5d a y s .R O R γt (a) and
IL-17 (b) expression was measured by FACS in CD4+ T cells. For comparison, CD4+ T cells were cultured alone with IL-1β, IL-6, and IL-23
for 5 days. Data (means ± SEM) are expressed as fold induction relative to vehicle (V) control. n = 10; ∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001.
(c) LC were also stimulated with either vehicle or PAF in the absence or presence of the PAFR antagonist WEB 2086 (10−5 M) and cocultured
withanti-CD3/CD28-activatedCD4+ Tc ellsfor5da ys.R ORγtexpressionwasmeasuredbyFACSinCD4+ Tcellsandexpressedasgeometric
mean (±SEM) ﬂuorescence intensity (MFI). n = 5; ∗∗P<0.01; ∗∗∗P<0.001.Mediators of Inﬂammation 7
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Figure 4: PAF-stimulated LC induce Th17 mRNA markers in cocultured T cells. Monocyte-derived LC were stimulated with graded
concentrations of PAF or its vehicle (ethanol; V) and cocultured with antiCD3/CD28-activated CD4+ T cells for 5 days. IL-17A (a), RORC2
(b), IL-21 (c), and IL-22 (d) mRNA expression was measured by real-time quantitative PCR in CD4+ T cells. For comparison, CD4+ Tc e l l s
were cultured alone with IL-1β, IL-6, and IL-23 for 5 days. Data (means ± SEM) are expressed as fold induction relative to vehicle (V)
control. n = 8; ∗P<0.05; ∗∗P<0.01.
in CD4+ T cells after 5 days. As shown in Figure 5(a),
addition of Ab directed against IL-23 or IL-6R resulted in
a markedly decreased induction of RORγt expression. In
contrast, neutralization of IL-15 had no eﬀect. Our data
suggest that IL-23 and IL-6, but not IL-15, are essential for
LC-dependent, PAF-induced Th17 development.
3.5. PAF-Induced Th17 Development Is Dependent on LC-
TC e l lC o n t a c t .Since antigen-presenting cells need to
physically interact with T cells at diﬀerent stages of
the immune response, we tested whether cell-cell contact
between PAF-primed LC and TCR-activated T cells was
essential for Th17 development. As shown in Figure 5(b),8 Mediators of Inﬂammation
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Figure 5: PAF-stimulated Th17 development is dependent on cytokines, LC-T cell contact and selected signaling pathways. (a) Monocyte-
derived LC were stimulated with either vehicle or PAF in the presence of neutralizing Ab to IL-15, IL-6R, and/or IL-23, or control Ig, and
cocultured with antiCD3/CD28-activated CD4+ T cells for 5 days. For comparison, CD4+ T cells were cultured alone with IL-1β,I L - 6a n d
IL-23 for 5 days in the absence or presence of the above-indicated neutralizing Ab. RORγt expression was measured by FACS in CD4+ Tc e l l s
and expressed as geometric mean (±SEM) ﬂuorescence intensity (MFI). n = 5; ∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001. (b) LC were stimulated
with either vehicle or PAF and cocultured with antiCD3/CD28-activated CD4+ T cells for 5 days with direct LC-T cell contact or separated
by a Transwell ﬁlter (LC in the top chamber, T cells in the bottom), in the absence or presence of neutralizing Ab to IL-6R or IL-23. RORγt
expression was measured by FACS in CD4+ T cells and expressed as geometric mean (±SEM) ﬂuorescence intensity (MFI). n = 5; ∗P<0.05;
∗∗∗P<0.001. (c) LC were stimulated with either vehicle or PAF and cocultured with antiCD3/CD28-activated CD4+ T cells for 5 days in the
absence or presence of inhibitors of Jak2, EGFR, NF-κB, or STAT3. RORγt expression was measured by FACS in CD4+ T cells and expressed
as geometric mean (±SEM) ﬂuorescence intensity (MFI). n = 4; ∗∗P<0.01; ∗∗∗P<0.001.
RORγt expression in CD4+ T cells was prevented when
LC were separated from T cells by a Transwell membrane,
indicating that indeed PAF-induced Th17 development was
also dependent on LC-T cell contact.
3.6. PAF-Induced Th17 Development Is Dependent on Jak2,
STAT3, NF-κB, and EGFR. We have previously shown that
PAFR signaling could induce Jak2 phosphorylation and
STAT3 translocation in monocytes [35]. Moreover, PAFMediators of Inﬂammation 9
had been shown to induce the production of heparin-
binding epidermal growth factor like growth factor (HB-
EGF) through an NF-κB-dependent mechanism [36]a n dt o
transactivate the epidermal growth factor receptor (EGFR)
[37]. STAT3 and NF-κBw e r ea l s of o u n dt ob er e q u i r e d
for IL-23 mediated IL-17 production [38]. When LC were
pretreated with cell-permeable inhibitors of Jak2, EGFR, NF-
κBo rS T A T 3 ,R O R γt expression in CD4+ Tc e l l sw a st o t a l l y
prevented(Figure 5(c)),suggestingthattheJak-STAT,NF-κB
and EGFR signaling pathways were involved in PAF-induced
Th17 development.
4. Discussion
The expression of IL-23 is highly enhanced in lesional
psoriatic skin and this Th17-inducing factor is produced by
keratinocytes, Langerhans cells, dermal dendritic cells and
macrophages [19]. The immunogenicity of skin correlates
with a substantial number of resident DCs including epi-
dermal Langerhans cells (LCs) and dermal DCs (DDCs),
which are both capable of activating na¨ ıve T cells [39, 40].
During the development of chronic cutaneous inﬂammatory
and autoimmune disorders, such as in psoriasis, Th17
and Th1 cells inﬁltrate the skin where resident DCs were
shown to have a role in the initiation and maintenance of
Th17 immunity [41, 42]. Diﬀerent observations suggested a
possible association of the inﬂammatory lipid mediator PAF
with psoriasis [29–32]. PAF is found in increased concen-
trations in inﬂammatory lesions and is a known regulator
of transcription of a variety of cytokines [26] including IL-
6. Moreover, PAF appears very early in inﬂammation and
c a ns t i m u l a t ea n db ep r o d u c e db yav a r i e t yo fc e l l ss u c ha s
monocytes,dendriticcells,andkeratinocytes.Inthiscontext,
we investigated whether PAF could aﬀect the development of
T h 1 7c e l l si nam o d e lo fL C - Tc e l lc o c u l t u r e .
In the present study we provide evidence that PAF
could eﬀectively modulate the development of Th17 cells.
First, we found that PAF induced a rapid expression of
IL-1β, IL-6 and IL-23 in human LC and keratinocytes,
three cytokines reported to be crucial for Th17 development
[1, 2]. Second, we observed that TCR-activated T cells
in coculture with PAF-stimulated LC, developed a Th17
phenotype with increased expression of the transcriptional
regulator RORγt (and its human RORC2 mRNA equivalent)
and associated molecules including IL-17A, IL-21 and IL-
22. Third, our ﬁndings demonstrate that blocking PAFR
in LC-T cell cocultures impaired the expression of the
transcriptional regulator RORγt and that using anti-IL-
6R and anti-IL-23 alone or in combination, abrogated the
inductionofRORγtexpressionbyPAF.Finally,wealsofound
that PAF-induced Th17 development was dependent on cell-
cell contact between LC and T cells and that PAF enhanced
the expression of Th17-associated markers via stimulation
of LC rather than T-cells. Taken together, these observations
suggest that generation of Th17 by LC is dependent on T
cell interaction with LC and the production, by the latter, of
cytokines such as IL-6 and IL-23 in response to PAF.
This kind of regulation of IL-17 production was also
reported for another G-protein-coupled receptor. Sphingo-
sine 1-phosphate (S1P), a biologically active lysophospho-
lipid that binds to its receptor S1P1, was shown to have an
eﬀect similar to IL-23 in terms of increasing Th17 develop-
ment from mouse splenic CD4+ T cells [43]. Moreover, in a
recent review article, Edwards and Constantinescu suggested
that the PAF/PAFR pathway may directly inﬂuence T cell
responses and favour a Th17 phenotype, but no actual data
were provided [28]. There are conﬂicting observations about
whether human T lymphocytes express PAFR or not. Some
authors reported that PAFR was not detectable on either
resting [44] or activated T cells [45], but others observed low
level expression on resting T cells which increased following
stimulation [28, 44]. However, in our model, TCR-activated
highly puriﬁed human CD4+ Tl y m p h o c y t e sl a c k e dP A F R
expression and were unable to functionally respond to PAF
stimulation. On the other hand, our results demonstrating
that PAF can stimulate human LC and keratinocytes are in
concordance with the literature which indicates that both
DC and keratinocytes express functional PAFR [22, 46]
and that PAF signalling activates LC migration [47]. As
seen in our results, a bell-shaped concentration-response
curve is regularly seen with GPCR ligands, where high
concentrations do not elicit as good a response as mid-range
concentrations. It is thought that autologous desensitization
andinternalizationofthereceptor,inresponsetohighligand
concentrations, may be responsible for this phenomenon.
IL-17AandIL-17Fbothinducetheproductionofvarious
cytokines and chemokines, including TNFα,I L - 1 β,I L - 6 ,
IL-8, CCL2 (MCP-1), granulocyte colony-stimulating factor
(G-CSF), as well as the expression of intercellular adhesion
molecule (ICAM)-1 by monocytes, airway epithelial cells,
vein endothelial cells, and ﬁbroblasts. These IL-17-induced
expression proﬁles can often be enhanced by TNFα and IFN-
γ [48]. In the context of the skin, IL-17 has been reported
to modulate the cytokine production and surface molecular
make-up of epidermal keratinocytes. IL-17 enhanced the
production of IL-6 and IL-8 in keratinocytes and induced a
weakexpressionofICAM-1andHLA-DR[41],whereasIFN-
γ and TNFα-induced production of RANTES was markedly
inhibited by IL-17 [49]. In addition, IL-17 has been reported
tomodulateﬁbroblastfunctionbyinducingtheirproduction
of IL-6, IL-8, IL-11, GROα, and G-CSF [48].
In addition to IL-17A and IL-17F, Th17 cells produce
other eﬀector cytokines, namely, IL-21 and IL-22 [6].
Neither IL-21 nor IL-22 are Th17-exclusive cytokines, but
are preferentially expressed in Th17 cells. IL-21 is produced
m a i n l yb yC D 4 + T cells [50]a sw e l la sb yN K Tc e l l s[ 51].
Recently, several groups simultaneously observed that IL-21
was produced by Th17 cells upon stimulation by IL-6 and
by IL-21 itself and exerted critical functions in Th17 cell
development [52–54]. The coexpression of IL-17 and IL-22
in Th17 cells suggests that the pathways that regulate these
two cytokines might be very similar [55]. Although IL-23 is
insuﬃcient to induce de novo IL-17 production from na¨ ıve
CD4+ T cells, IL-23 alone promotes IL-22 production from
many diﬀerent immune cell types. IL-6 alone is suﬃcient
for the induction of IL-22 from na¨ ıve CD4+ T cells. IL-22,10 Mediators of Inﬂammation
therefore, might be an obvious downstream factor of IL-
23 that mediates the crosstalk between inﬁltrating immune
cells, especially T cells, and keratinocytes in psoriatic skin.
Injection of IL-23 into a mouse ear causes an inﬂammatory
skin phenotype, characterized by leukocyte inﬁltration [54].
The inﬁltrating CD4+ T cells display a Th17 cell phenotype
with the expression of both IL-17 and IL-22. In addition to
IL-21 and IL-22, other cytokines such as TNFα and IL-1β,
which are not speciﬁcally produced by Th17 cells, have been
proposed to have an additional role in the ampliﬁcation of
Th17responses[56,57].PAF,aknownactivatorofIL-1β and
TNFα [58] could also participate in such an ampliﬁcation
loop. Recently, TLR2-activated human LC also were shown
to promote the polarization of Th cells into Th17 cells via
the production of IL-1β,T G F β,a n dI L - 2 3[ 59].
Thus, PAF/PAF-R interactions may be involved in the
early events leading to Th17 diﬀerentiation and trigger a self-
ampliﬁcation process. PAF may contribute to the creation of
a proinﬂammatory environment that would skew cytokine
production in favour of Th17 development. During the
preparation of the present paper, Singh et al. [60]r e p o r t e d
that in vivo blockade of PAF inhibited the development of
psoriasis-like disease in a transgenic mouse model and the
concomitant Th17 phenotype.
5. Conclusion
In the present work, we showed that PAF stimulates LC and
keratinocytes to produce IL-6 and IL-23. Moreover, activated
T cells in coculture with PAF-stimulated LC develop a Th17
phenotype with increased expression of the transcriptional
regulator RORγt and enhanced production of IL-17, IL-
21 and IL-22. These eﬀects are blocked by a PAF receptor
antagonist and neutralizing antibodies to IL-6 and IL-23.
These observations suggest that PAF can contribute to the
diﬀerentiation of activated T cells into Th17 by inducing LC
to produce IL-6 and IL-23. This may constitute a previously
unknown stimulus for the development and persistence of
inﬂammatory processes that could be amenable to pharma-
cologic intervention.
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